__________________________________________________________________________________________________________
Evergen analyze hundreds of images and processes reports in under ten seconds, enabling us to make quick data-driven decisions.”
From our conversation, Kevin’ s expertise and commitment to patient care shines through. Thinking about his career and the wider industry, Kevin shares:“ I have more than 30 years of experience in the medtech industry, and I became enamored with the tissue side of the sector. It fascinates me to take tissue, whether it’ s animal-based xenograft or human-based allograft, and transform it into life-enhancing products. I’ ve been at Evergen for two years now, and it’ s amazing to be part of a business that’ s a new kind of partner for the industry – one that focuses on developing biomaterial solutions that address unmet clinical needs. What makes Evergen unique is that we don’ t advocate a specific biomaterial over another, but instead work with clinicians, OEMs, and surgeons to understand their challenges and demands. As Evergen continues to transform, I’ m proud to drive our unwavering commitment to quality and continuous improvement.”
With an extensive portfolio of biomaterial solutions and an unrivaled commitment to patient care, Evergen is redefining what it means to be a partner in the medtech industry. As talk turns to the future, Kevin shares Evergen’ s strategy:“ We’ re seeing increased demand across all clinical segments, especially for soft tissue in the sports medicine and plastic surgery and reconstructive surgery clinical segments. To meet increased demand, we’ re increasing our capabilities at several of our facilities and working to improve our operational efficiency. This includes finding new ways to implement AI within manual processes that not only allow us to be more efficient, but also to be more thoughtful about the products and processes we conduct.
“ The last couple of years have seen us focus on integrating our acquired companies, but 2026 is about execution and scaling our CDMO platform while maintaining the quality we’ re known for and consistently delivering for our customers. We strive to be a reliable and committed partner with a patient-first mindset, which means we’ re always keen to progress and engage in innovative product development.
“ From concept to commercialization, I want Evergen to be recognized as the key CDMO partner in regenerative medicine, known for world-class quality, dependable supply, and an ability to help customers develop life-enhancing biomaterial solutions,” Kevin concludes.“ Strategically, we’ ll continue to expand our capabilities and bring our biomaterial solutions to more patients around the world while never compromising our standards.” ■
www. evergenbio. com
manufacturing-today. com 253